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Background: Current guidelines for breast cancer treatment recommend completion axillary lymph node
dissection (CALND) following in case of positive sentinel lymph node (SLN) metastasis, which only in 35%
e70% shows additional nodal metastases. Several nomograms and scoring systems have been created to
predict the risk of metastasis in non-SLNs. The aim of the study was to identify individual patient risk for
non-sentinel lymph node metastasis by validating with MSKCC nomogram and to evaluate the variability
within a group of SLN-positive breast cancer patients with the ﬁnal goal of avoiding unnecessary CALND.
Patients and methods: We retrospectively evaluated 1496 primary breast cancer patients. 324 women
with a positive SLN who underwent CALND were identiﬁed. The predictive accuracy was measured and
compared with the MSKCC nomogram by the area under the receiver operating characteristic curve.
Receiver operating characteristic (ROC) curve was drawn on the basis of the sensitivity and speciﬁcity,
and the area under the curve (AUC) was calculated.
Results: At least one metastatic non-SLN were identiﬁed in 88/324 (27.2%) patients. Tumor size, tumor
type, tumor grade, number of positive SLNs and number of negative SLNs were signiﬁcantly associated
with non-SLN status in multivariate analyses. The MSKCC nomogram showed an AUC value of 0.738 (95%
conﬁdence interval ¼ 0.682e0.793) after the validation for our collectives.
Conclusions: The MSKCC nomogram showed a good prediction for the non-SLN metastasis and performed
adequately in our patient collective. Therefore, for the use of nomogram, validation with other pop-
ulations of patients is strongly suggested.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Axillary lymph node status is an essential and important prog-
nostic factor for breast cancer patients. The determination andþ886 62766676.
uo), Darren_chen@cch.org.tw
g).
ciates Ltd. Published by Elsevier Ltdiagnosis is crucial for the treatment decision. Recently, the
sentinel lymph node (SLN) biopsy has replaced in adequate cases
the conventional completion axillary lymph node dissection
(CALND) as axillary staging of breast cancer.1e4 Therefore, CALND is
recommended in case of a positive SLN. However, in patients
diagnosed with positive SLN, according to some reports the inci-
dence of non-SLN involvement differ from several studies, the
range varies from 35% to 70% of patients.2,5e10 To clarify the inﬂu-
ence of additional nodal dissection in cases of positive SLN to thed. All rights reserved.
Table 1
Comparison of descriptive characteristics of the MSKCC and NCKUH/CCH collectives.
Characteristics MSKCC
(n ¼ 373)
NCKUH/CCH
(n ¼ 324)
p-Value
n % n %
Age (years) 0.0002
&50 157 42.1 182 56.2
>50 216 57.9 142 43.8
Pathological size (cm) <0.0001
&0.5 13 3.5 9 2.8
0.6e1.0 49 13.1 17 5.2
1.1e2.0 166 44.5 132 40.6
2.1e3.0 93 24.9 97 29.8
3.1e5.0 41 11.0 49 15.1
>5.1 11 2.9 20 6.2
Tumor type and nuclear grade <0.0001
Ductal type, grade I 11 2.9 60 18.5
Ductal type, grade II 175 46.9 173 53.2
Ductal type, grade III 129 34.6 53 16.3
Lobular type 58 15.5 12 3.7
Others 0 0 20 6.2
LVI <0.0001
No 219 58.7 100 30.8
Yes 154 41.3 217 66.8
Multifocal <0.0001
No 241 64.6 315 96.9
Yes 132 35.4 9 2.8
ER 0.3742
Negative 83 22.3 63 19.4
Positive 290 77.7 260 80.0
Positive SLN (n) 0.1376
1 265 71.0 231 71.3
2 75 20.1 59 18.2
3 21 5.6 16 4.9
4 8 2.1 5 1.5
S5 4 1.1 13 4.0
Negative SLN (n) <0.0001
0 132 35.4 125 38.6
1 79 21.2 70 21.6
2 72 19.3 25 7.7
3 41 11.0 31 9.6
4 22 5.9 20 6.2
S5 27 7.2 53 16.3
LVI: lymphovascular invasion, ER: estrogen receptor, SLN: sentinel lymph node.
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SLN biopsy alone compared with CALND did not result in inferior
survival.11
With the emphasis to reduce the unnecessary CALND and
improve the quality of life in SLN positive breast cancer patient,
several authors have suggested nomograms and scoring systems to
predict the risk of non-SLNmetastases (NSLNM).12e15 Thesemodels
may provide individual probability related to the beneﬁts and risks
of further lymph node metastasis, and help the physician and pa-
tients in decision making of additional CALND.
One of the ﬁrst and most validated nomogram is the model
developed from Van Zee et al. at Memorial SloaneKettering Cancer
Center (MSKCC) that addressed to predict the non-SLN status
avoiding the unnecessary CALND. This nomogram is based on 9
clinicopathological variables including age, tumor size, histology
type, nuclear grade, lymphovascular invasion (LVI), multifocality,
estrogen receptor (ER) status, number of positive SLNs, and number
of negative SLNs. The accuracy was validated using internal and
external cohorts.12,16 The validations were also performed in
different institutions with quite different result.15,17e20 The possible
reasons for the discrepancy, might have been heterogenous, such as
detection method of SLN, histopathological characteristics or pa-
tient ethnicity. Furthermore, some these studies have concluded
that the use of MSKCC nomogram to predict non-SLN metastasis in
breast cancer patients with positive SLN should be aware.15,20
Taiwanese breast cancer patients usually have a younger age
compared to Western population. A deeper understanding in de-
tails and performance of the nomogram, can provide us which
factors are determinant in the risk of further lymph node metas-
tasis, especially for Asian population.
The aims of this study are to validate the predicted probabilities
of MSKCC nomogram in our positive SLN patients and to evaluate
the variability in outcomes within a group of clinically relevant
SLN-positive breast cancer patients.
2. Patients and methods
We retrospectively evaluated 1496 patients with primary invasive breast cancer
who underwent SLN biopsy at National Cheng Kung University Hospital and
Changhua Christian Hospital, Taiwan between July 1999 and November 2011. All
clinicopathologic data were collected from medical, surgical, and pathologic data-
base of both institutions. The data were conﬁrmed on chart review.
Exclusion criteria were palpable regional lymph nodes, neoadjuvant chemo- or
radiotherapy, pregnancy, known allergic reactions to blue dye or isotope, previous
surgery in the ipsilateral breast, distant metastasis at diagnosis and those with
incomplete data required for the nomogram validation.
All of these breast cancer patients received SLNB using both radioisotope and
blue dye. The SLN biopsy performed, guided by a hand-held gamma probe (Navi-
gator; USSC, Norwalk, CT). A CALND was performed in the event of a positive SLNB
diagnosed perioperatively (by frozen section) or postoperatively.
Among them, 324 patients (21.7%) with one or more SLN involved and CALND
were selected from the database to process this study. The study was approved by
the ethics committee of NCKUH and CCH (IRB No: B-ER-101-200). Informed consent
was obtained from all patients included in the study.
The data collection includes the following characteristics: patient age, patho-
logical tumor size, histology type, tumor grade, estrogen and progesterone receptor
(ER and PR), HER2/Neu status, the presence of lymphovascular invasion (LVI), the
presence of multifocal disease, number of positive SLNs, and number of negative
SLNs.
3. Data analysis
c2 test for categorical variables and two-sample independent t
test for continuous variables were used to compare the differences
in characteristic variables between MSKCC and our cohort. Firstly,
we validated the performances of the MSKCC nomogram (www.
mskcc.org/nomograms) through the estimated values of the AUC,
as well as the conﬁdence intervals (CI) at the level of 95% and of the
error rate (ER). The area under the receiver operating characteristic(ROC) curve (AUC) was performed to measure the discrimination of
nomograms. A ROC curve test resulted of Hanley and McNeil could
be applied in the comparison of different screening nomograms
developed byMSKCC using 324 patients database.21 We located the
point on the ROC plot to be the optimal cut-off point, where the
distance from (0, 1) corner to ROC curve is minimum. Values higher
than 0.70 represented considerable discrimination. In order to
reduce the over-ﬁtting problem, leave- one- out cross evalidation
(LOOCV) was used to adjust the ROC curve. Cross-validation
involved partitioning a sample of data into complementary
training and testing subsets, performing the analysis on the
training set and validating the analysis on the other testing set.
LOOCV used a single observation from the original sample as the
validation data, and the remaining observation as the training data.
Each adjusted predicted probability was calculated to form the ROC
curve. The adjusted predicted probability was also used to form the
predicted v.s. observed plot.
Patients were divided into ten deciles on the basis of the sorting
predicted probabilities evaluated from our nomogram. For each
decile, the observed outcome probability was compared with the
mean predicted probability and the result was shown graphically.
Pearson correlation was performed to determine the linear rela-
tionship. Univariate and multivariate analysis were performed to
determine predictors related to the non-SLN metastasis. We set p
value less than 0.2 for selection of variables to include into logistic
Table 2
Multivariate analysis of the NCKUH/CCH patient population.
Characteristic Odds ratio 95% CI p-Value
Pathologic tumor size 1.523 1.184e1.959 0.001
Tumor type and grade 0.042
IDCA, grade I Reference
IDCA, grade II 0.650 0.112e3.772
IDCA, grade III 2.674 0.568e12.599
Lobular ca 2.554 0.478e13.661
Others 1.573 0.179e13.808
ER 0.326
Positive 1.559 0.642e3.787
Negative Reference
Numbers of positive SLN 1.273 0.997e1.624 0.05
Numbers of negative SLN 0.732 0.623e0.860 <0.0001
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statistical analysis was performed using SPSS 17.0.4. Results
The overall descriptive clinical and histopathological charac-
teristics of 373 positive SLN patients from MSKCC and 324 positive
SLN patients who underwent CALND from our collective are listed
in Table 1. Comparing to the MSKCC population, our patients
showed a younger age (p ¼ 0.0002), larger tumor size by the
diagnosis of breast cancer (p < 0.0001), lower tumor grade
(p < 0.0001), higher incidence of LVI (p < 0.0001), lower incidence
of multifocality (p < 0.0001) and higher negative SLN number
(p < 0.0001). The proportion of estrogen receptor status and pos-
itive SLN number were quite similar in the both collective.
Metastatic non-sentinel lymph nodes were identiﬁed in 88/324
(27.2%) patients. Tumor size, tumor type, tumor grade, number of
positive SLNs and number of negative SLNs were signiﬁcantlyFig. 1. Calibration plot for the MSKCC nomogram in our patients. The entire cohort was cla
probability was calculated. A calibration plot was drawn showing the actual versus predictassociated with non-SLN status in the univariate analyses. In the
multivariate logistic regression analyses, tumor size, tumor type,
tumor grade and number of positive SLNs and number of negative
SLNs were also signiﬁcantly associated with non-SLN metastasis
(Table 2).
For assessment of the nomogram accuracy, calibration plot for
observed probability against the predicted probability was calcu-
lated. Fig. 1 showed the observed probability of our collective using
the MSKCC nomogram (r ¼ 0.734). On the basis of the calibration
plot, the MSKCC nomogram tends to underestimate the risk of the
probability of non-SLN metastasis. To determine the discrimination
of the nomograms, the area under the ROC curve reports estimated
coefﬁcients of the ﬁtted model. The overall predictive accuracy of
the MSKCC nomogram in our patient collective, as measured by the
area under ROC curve was 0.738 (95% conﬁdence interval ¼ 0.682e
0.793) (Fig. 2).
5. Discussion
Axillary lymph node status is an important prognostic and
predictive factor for the staging and treatment of breast cancer.
Newly, SLN is accepted as a standard axillary lymph node staging
for clinically axillary negative breast cancer patients.1e4 In case of
positive SLN, a CALND remains the standard therapy. However,
according to several publications the NSLNM is ranged from 35 to
70%.2,5e10 Bilimoria et al. observed in a study with 97 314 patients
who underwent SLN biopsy between 1998 and 2005, that there are
no statistically signiﬁcant differences in axillary recurrence and
overall survival for SLNB alone versus SLNB with CALND (HR, 0.58;
95% CI, 0.32e1.06, HR, 0.89; 95% CI, 0.76e1.04, respectively).22
Recently, the American College of Surgeons Oncology Group
(ACO-SOG) Z0011 trial studied the effect of CALND on survival of
patients with positive SLN. They concluded after a median follow
up of 6.3 years no statistically differences in local axillaryssiﬁed in deciles according to their predicted probabilities. For each group, the actual
ed probability for each decile.
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2 groups.11,23
Several authors have created and validated nomograms and
scoring systems with the goals to ﬁnd the patient subgroup of non-
SLNmetastasis and diminish the rate of unnecessary CALND in SLN-
positive patients.12e15,24e26 Hence, Van Zee and colleagues devel-
oped a nomogram to estimate the risk of non-SLN metastasis using
the database of Memorial SloaneKettering Cancer Center
(MSKCC).12 The nomogram has been validated at European and
Asian institutions. However, the results showed divergent out-
comes. The AUC is calculating to assess the discriminative power
across risk levels. In the international comparison, the AUC values
vary from 0.58 to 0.78 (Table 3).14,20,24,25,27e49 In this table, we have
listed the studies with the AUC above and below 0.7. The probably
reasons for the wide discrepancy might be age, tumor size, tumor
grade, histological type, heterogeneity in histopathological assess-
ment and staining of SLN, SLN mapping techniques, proportion of
the positive and negative SLN or micrometastasis. However, some
opponent for the nomogram showed negative result by using the
nomogram for the prediction of non-SLN metastasis.15,45,50 The
AUC value after validation with the MSKCC nomogram in our pa-
tient population showed 0.738. To our knowledge, this is the largest
external validation of MSKCC nomogram for predicting the likeli-
hood of non-SLN metastasis with a positive sentinel lymph node in
Asian breast cancer population.
Several nomograms for prediction of non-SLN metastasis after
positive SLN have incorporated prognostic factor tumor size as
important parameter.12,13,15 In the multivariate analysis showed
that the tumor size is a strong independent predictor of non-SLNFig. 2. Receiver-operating characteristic (ROC) curve calculation for NCKUH/CCH col-
lectives using the MSKCC nomogram. The 45 line reﬂects an AUC of 0.5, which
indicated a score equal to chance, without discriminating power. 95% CI indicated
conﬁdence interval.metastasis. This result is similar to many groups.5,20,24,26,39,49,51e54
Therefore, proportion of SLN and number of positive or negative
SLN is a signiﬁcant predictor also in several publications.13,29,39,42,49
Gur et al. used in their nomogram the proportion of positive SLN
among total SLN.40 In our multivariate analysis, the number of
positive and negative SLN is independent predictors of non-SLN
metastasis. This is consistent with the model of MSKCC. However,
in the study of Cho et al. showed no statistically signiﬁcance.24
Comparing to the other nomograms, only the MSKCC and our
nomogram has included both factors number of positive and
negative SN as signiﬁcant predictors.
ER receptor status is an important prognostic and predictive
factor for breast cancer. Not only in the prognosis even in the
treatment. Positive ER receptor status is considered as a favorable
prognosis. Interesting, in the non-SLN metastasis the ER receptor
showed a vice versa effect in our study. That means ER receptor
positive breast cancer patients tend to have SLN metastasis. This
result is consistent with other studies.25,36,55 In the nomograms of
MSKCC and Cambridge, tumor grade is included as independent
predictor of non-SLNmetastasis.12,14 In the further validation study,
grading is correlated with the probability of SLN metastasis.20,51,54
In our uni- and multivariate analysis, the tumor type and grading
plays also an essential role.
We agreed that there are some limitations of the applicability of
the nomogram in the clinical practice. In this study, we do not take
into consideration several possible statistically signiﬁcant pre-
dictors, such size of metastasis and histopathological assessment
and staining of SLN. Alran et al. showed in a French collective of 588
positive SLN patients who underwent completion CALND an area
under the receiver operating characteristic curve (ROC) of 0.724Table 3
Validation of the Memorial SloaneKettering cancer center nomogram in different
countries.
Authors Country Year Patients
with
positive
SLN
AUC
Cho et al.24 Korea 2008 82 0.786
Klar et al.33 Germany 2009 118 0.78
Coutant et al.34 France 2009 561 0.78
Smidt et al.27 The Netherlands 2005 222 0.77
Lombardi et al.25 Italy 2011 139 0.76
Soni et al.28 Australia 2005 149 0.75
Kuo et al. Taiwan 2013 324 0.738
Hidar et al.44 Tunisia 2011 87 0.73
Sasada et al.47 Japan 2012 116 0.73
Alran et al.29 France 2007 588 0.724
Zgajnar et al.30 Slovenia 2007 276 0.72
Amanti et al.35 Italy 2009 61 0.72
D’Eredita et al.45 Italy 2011 103 0.712
Ponzone et al.31 Italy 2007 186 0.71
Ramjeesingh et al.36 Canada 2009 90 0.71
Van la Parra et al.37 The Netherlands 2009 182 0.71/0.75a
Gur et al.40 Turkey 2010 607 0.705
Gur et al.38 Turkey 2009 319 0.70
Tan et al.49 Singapore 2011 60 0.6938
Poirier et al.32 Canada 2008 209 0.687
Piñero et al.48 Spain 2012 501 0.684
Pal et al.14 United Kingdom 2008 118 0.68
Coufal et al.39 Czech Republic/Hungary 2009 330 0.68
Van der Hoven et al.41 The Netherlands 2010 168 0.68
Sanjuán et al.42 Spain 2010 114 0.67
Fougo et al.46 Portugal 2011 98 0.67
Moghaddam et al.43 United Kingdom 2010 108 0.63
Klar et al.20 Germany 2008 98 0.58
Series with AUC < 0.70 are in bold.
a Method 1: all metastasis visible by serial hematoxylin and eosin (HE)/method 2:
macrometastasis detected by routine HE, micrometastasis by serial HE and isolated
tumor cells by immunohistochemistry.
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predictive value when was applied to micrometastasis detected by
hemotoxylin and eosin staining with an AUC of 0.538 (range,
0.423e0.653). They concluded that the MSKCC nomogram was not
reliable non-SLN predictive model for micrometastatic positive
SLN.29 Therefore, Kocsis et al. failed to validate the accuracy of
MSKCC nomogram in their study with 140 patients in Hungary.
They hypothesized that difference in the pathologic assessment
leads to the discrepancy of the validation results. Therefore, they
proposed more detailed section with thinner sections may
contribute to the detection rate of metastasis.50 Also in some study
the MSKCC nomogram did not predict accurately NSLNM in the
patient group with micrometastasis.38,56 The methods for patho-
logical assessments differ strongly among the studies. Lambert
et al. concluded that the use of touch imprint cytology (TIC) is an
accurate for intraoperative assessment of SLN.19 However, Kocsis
and colleagues have validated the use of intraoperative assessment
with TIC versus frozen section. They found that both methods
showed similar result.50 Therefore, H&E staining by frozen section
remain as the method for detection of SLN.
Finally, one of the limitations, is the design of the study. This is a
regional, retrospective study with the aim to validate MSKCC
nomogram that more suitable for population with different
descriptive characteristics. Indeed, the area under the ROC curve is
not perfect. However, the discriminative power of nomogram
showed a good prediction for our population In addition, by accu-
mulating more clinical experiences and improvement of prediction
model, we hoped to provide a more accurate and reliable nomo-
gram, which can validate with prospective, randomized and inde-
pendent collective. Therefore, a validation study using multi-
institutional database will enhance the discriminative power of
nomogram. We encourage before its use in the clinical practice of
themodel should be validatedwith database of different institution
and patient collective.
6. Conclusion
There are no perfect nomograms which can predict or give a
straightforward answer to patients who need CALND in case of
positive SLN. Therefore, with the improvement of the model by
validation, we hope to ﬁnd out the predictive factors of low risk
subgroup. Together with assessment of clinical status and analysis
of nomogrammaybe can reduce the rate of unnecessary CALND. By
use of any nomogram, the physician should validate the perfor-
mance of each nomogram, and ﬁnd out the accurate and suitable
nomogram for each patients population.
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